Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

ACADIA Pharmaceuticals Inc (ACAD) reports a robust 19% increase in total revenue, driven by significant sales growth in DAYBUE and NUPLAZID, alongside strategic international expansions.

EVP Thompson explained the dose selection rationale and noted limited definitive evidence for GLP-1 efficacy in Prader-Willi. Analysts also raised concerns about DAYBUE's persistency metrics and ...

Wisconsin’s special education reimbursement rate has been a concern for public school advocates for many years, but with ...

This initiative aligns with Sandoz’s ongoing efforts to support Egypt’s Vision 2030 and local healthcare authorities’ ...

Aardvark Therapeutics, Inc.’s AARD share price has dipped by 13.88%, which has investors questioning if this is right time to buy.

Q1 2025 Management View CEO Catherine Owen Adams highlighted a strong start to 2025 with quarterly revenues of $244.3 million, a year-over-year increase of 19%. She emphasized growth in both DAYBUE ...

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that ...

Q1 2025 Earnings Call Transcript May 7, 2025 ACADIA Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $0.11, ...